Here is a dense scientific post from the SENS Foundation that might be better read back to front, starting with the research partnership announcement at the end. Some fraction of degenerative aging is caused by an accumulation of various forms of amyloids between cells, probably the best known of which is that involved in Alzheimer's disease. One goal for the Strategies for Engineered Negligible Senescence (SENS) approach to aging is to establish a general technology platform that can be used to remove any form of amyloid: "In late 2008, we reviewed then-unpublished work by Dr. Mark Pepys, who was working on an ambitious project anticipated to allow for the disaggregation of nearly all disease-associated amyloids. ... I am therefore delighted to have the privilege to be given permission [to] make the first public announcement that the Supercentenarian Research Foundation has recently helped to facilitate a collaboration between researchers already working in amyloid diseases, to develop antibodies to cleave aggregated wild-type and mutant transthyretin - the form responsible for senile cardiac amyloidosis (a prevalent, but not exclusive, cardiac amyloidosis in supercentenarians)."

View the Article Under Discussion: http://www.sens.org/node/831

Read More Longevity Meme Commentary: http://www.longevitymeme.org/news/